Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving ...

Healthcare & Pharmaceuticalscategory· March 28, 2025 Merck plans to launch US subcutaneous version of Keytruda on October 1 Merck & Co said on Thursday that it plans to launch a subcutaneously ...

Keytruda, approved for several types of cancer ... Both the products are witnessing a strong launch. Merck has other promising candidates in its late-stage pipeline, such as MK-0616, an oral ...

The health sector faces challenges as Novo Nordisk's sales projections dim, Johnson & Johnson's unit faces hefty fines, and ...